Key Points
- Insider sale: Director Scott Bizily sold 1,635 shares on December 16 at an average price of $10.90 for $17,821.50, cutting his stake by 31.27% to 3,594 shares (about $39,175).
- This transaction is part of a string of recent disposals by Bizily, including sales on Nov 17 (1,635 shares at $10.59), Oct 24 (2,678 at $12.00), Oct 16 (1,635 at $10.17), Oct 9 (2,408 at $10.00) and Sep 23 (2,407 at $8.00), indicating a sustained insider sell-off.
- Company context: FDMT shares opened at $8.68 with a market cap of roughly $496M and continuing negative earnings and revenue, while analysts are mixed but show a consensus "Moderate Buy" with a $28.70 target.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $10.90, for a total value of $17,821.50. Following the completion of the transaction, the insider owned 3,594 shares in the company, valued at approximately $39,174.60. This trade represents a 31.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Scott Bizily also recently made the following trade(s):
- On Monday, November 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.59, for a total value of $17,314.65.
- On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $32,136.00.
- On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $16,627.95.
- On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total value of $24,080.00.
- On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $8.00, for a total transaction of $19,256.00.
4D Molecular Therapeutics Stock Down 0.1%
Shares of NASDAQ:FDMT opened at $8.68 on Friday. The stock has a market capitalization of $495.89 million, a PE ratio of -2.31 and a beta of 2.96. The firm's 50 day moving average price is $10.68 and its 200-day moving average price is $7.50. 4D Molecular Therapeutics, Inc. has a twelve month low of $2.23 and a twelve month high of $12.34.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million during the quarter, compared to analysts' expectations of $0.40 million. Analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on FDMT. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley raised 4D Molecular Therapeutics from an "underweight" rating to an "equal weight" rating in a research note on Friday, November 7th. Barclays cut their price objective on 4D Molecular Therapeutics from $38.00 to $33.00 and set an "overweight" rating for the company in a research note on Tuesday, November 11th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, December 6th. Finally, Leerink Partners reaffirmed an "outperform" rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $28.70.
Read Our Latest Stock Report on FDMT
Institutional Trading of 4D Molecular Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC grew its holdings in 4D Molecular Therapeutics by 1,103.4% during the 1st quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock valued at $1,290,000 after buying an additional 367,317 shares in the last quarter. Invesco Ltd. boosted its position in shares of 4D Molecular Therapeutics by 318.3% during the first quarter. Invesco Ltd. now owns 117,768 shares of the company's stock worth $380,000 after acquiring an additional 89,611 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in 4D Molecular Therapeutics during the first quarter valued at $63,000. Nuveen LLC purchased a new position in 4D Molecular Therapeutics during the first quarter valued at $486,000. Finally, Kera Capital Partners Inc. bought a new stake in 4D Molecular Therapeutics in the 2nd quarter valued at $89,000. Institutional investors own 99.27% of the company's stock.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.
4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
